Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > BioSante Pharmaceuticals Initiates Phase III Study of LibiGelŪ

December 28th, 2006

BioSante Pharmaceuticals Initiates Phase III Study of LibiGelŪ

Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) announced today that it has initiated a Phase III safety and efficacy trial of LibiGelŪ (transdermal testosterone gel) in the treatment of female sexual dysfunction (FSD). The double-blind, placebo-controlled Phase III trial will enroll approximately 360 surgically menopausal women for a six-month clinical trial, conducted under a Phase III protocol and investigational new drug application (IND) reviewed by and on file with the U.S. Food and Drug Administration (FDA).

Source:
businesswire.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015

Black phosphorus is new 'wonder material' for improving optical communication March 3rd, 2015

Heightened Efficiency in Purification of Wastewater Using Nanomembranes March 3rd, 2015

Human Interest/Art

2015 Nanonics Image Contest January 29th, 2015

OCSiAl supports NanoART Imagery Contest January 23rd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

Oxford Instruments Asylum Research Announces AFM Image Contest Winners January 11th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE